Palisade Bio Receives FDA IND Clearance for PALI-2108, Paving Way for Phase 2 ASCENTRA-UC

What happened

Palisade Bio announced FDA clearance of its IND for PALI-2108 in ulcerative colitis, allowing the initiation of the global Phase 2 ASCENTRA-UC study targeting up to 204 patients. This milestone, expected in the company's guidance, validates the regulatory path using Canadian Phase 1 data and removes a key near-term risk. However, the stock still faces binary outcome risk from Phase 2 efficacy readouts, which are not expected until late 2027. The company's cash runway from the October 2025 raise should fund through these readouts, but additional dilution remains a possibility.

Implication

The FDA acceptance without requiring additional US studies is a positive signal, increasing the probability of the bull scenario. However, the fundamental binary risk remains, and investors should focus on enrollment progress and safety signals. The thesis remains 'WAIT' until Phase 2 efficacy data emerges.

Thesis delta

The FDA's IND clearance removes a key regulatory risk and aligns with the base case, incrementally supporting the bull case. The primary risk now shifts to Phase 2 efficacy and safety, rather than regulatory hurdles. The previous assessment of balanced risk/reward at current prices remains unchanged, as the stock still prices in success before data.